{"_id": "65013a5cfddc0bb1312fb036", "booleanRepresentation": "{\n    \"$and\": [\n        {\"age between 18 and 79 years old\"},\n        {\"locoregionally recurrent or second primary HNSCC in a previously radiated field\"},\n        {\"underwent surgery with gross total resection and randomized within 8 weeks of surgery\"},\n        {\n            \"$and\": [\n                {\"positive margins and/or extra nodal extension (ENE)\"},\n                {\n                    \"$or\": [\n                        {\"positive margins defined as malignancy at or within 1 mm of the margin\"},\n                        {\"high grade dysplasia (i.e. carcinoma in situ) at the margin\"}\n                    ]\n                },\n                {\"ENE may be either gross or microscopic\"}\n            ]\n        },\n        {\"PD-L1 Combined Positive Score (CPS) >= 1 in a Clinical Laboratory Improvement Act (CLIA) certified laboratory\"},\n        {\"prior radiation to the area of recurrent or second primary tumor\"},\n        {\"completed prior radiation a minimum of 6 months prior to randomization\"},\n        {\"no evidence of distant disease based on baseline imaging done within 28 days prior to randomization\"},\n        {\"no anti-PD-1/PD-L1 therapy for recurrent disease\"},\n        {\"Eastern Cooperative Oncology Group (ECOG) performance status 0-1\"},\n        {\"ability to understand and willingness to sign a written informed consent document\"},\n        {\n            \"$or\": [\n                {\"not pregnant\"},\n                {\"not breastfeeding\"}\n            ]\n        },\n        {\n            \"$and\": [\n                {\"not expecting to conceive or father children\"},\n                {\"using accepted and effective method(s) of contraception or abstaining from sexual intercourse while on study treatment, and continue for 120 days after the last dose of study treatment\"}\n            ]\n        },\n        {\"ANC >= 1,500/mcL (obtained =< 28 days prior to protocol randomization)\"},\n        {\"platelets >= 100,000/mcL (obtained =< 28 days prior to protocol randomization)\"},\n        {\"total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained =< 28 days prior to protocol randomization)\"},\n        {\"Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional ULN (obtained =< 28 days prior to protocol randomization)\"},\n        {\"Creatinine clearance > 30 ml/min using the Cockcroft-Gault formula (obtained =< 28 days prior to protocol randomization)\"},\n        {\"no current active infection that requires systemic treatment at time of randomization\"},\n        {\"no history of non-infectious pneumonitis requiring steroids within 3 years prior to randomization\"},\n        {\"no history of solid organ transplant or stem cell transplant\"},\n        {\n            \"$not\": {\n                \"$and\": [\n                    {\"not on immunosuppressive medication within 7 days prior to randomization\"},\n                    {\n                        \"$or\": [\n                            {\"intranasal, inhaled, topical steroids, or local steroid injection\"},\n                            {\"systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent\"},\n                            {\"steroids as premedication for hypersensitivity reactions\"}\n                        ]\n                    }\n                ]\n            }\n        },\n        {\"clinical risk assessment of cardiac function using the New York Heart Association Functional classification\"},\n        {\"no live vaccine within 30 days prior to the first dose of study drug\"},\n        {\"no severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients\"},\n        {\n            \"$not\": {\n                \"$and\": [\n                    {\"no active autoimmune disease that has required systemic treatment in past 2 years\"},\n                    {\"replacement therapy is not considered a form of systemic treatment\"}\n                ]\n            }\n        },\n        {\"no known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study\"},\n        {\n            \"$or\": [\n                {\n                    \"$and\": [\n                        {\"HIV-infected patients on effective anti-retroviral therapy\"},\n                        {\"undetectable viral load within 6 months\"}\n                    ]\n                },\n                {\n                    \"$not\": {\n                        \"$or\": [\n                            {\"known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive)\"},\n                            {\"known active hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection\"}\n                        ]\n                    }\n                }\n            ]\n        }\n    ]\n}", "nctId": "NCT04671667", "title": "A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features"}